JP2010507567A5 - - Google Patents

Download PDF

Info

Publication number
JP2010507567A5
JP2010507567A5 JP2009523960A JP2009523960A JP2010507567A5 JP 2010507567 A5 JP2010507567 A5 JP 2010507567A5 JP 2009523960 A JP2009523960 A JP 2009523960A JP 2009523960 A JP2009523960 A JP 2009523960A JP 2010507567 A5 JP2010507567 A5 JP 2010507567A5
Authority
JP
Japan
Prior art keywords
use according
pharmaceutically acceptable
cxcr4 inhibitor
acceptable salt
cxcr2 agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009523960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010507567A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/075376 external-priority patent/WO2008019371A1/en
Publication of JP2010507567A publication Critical patent/JP2010507567A/ja
Publication of JP2010507567A5 publication Critical patent/JP2010507567A5/ja
Withdrawn legal-status Critical Current

Links

JP2009523960A 2006-08-07 2007-08-07 併用療法 Withdrawn JP2010507567A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83640906P 2006-08-07 2006-08-07
PCT/US2007/075376 WO2008019371A1 (en) 2006-08-07 2007-08-07 Combination therapy

Publications (2)

Publication Number Publication Date
JP2010507567A JP2010507567A (ja) 2010-03-11
JP2010507567A5 true JP2010507567A5 (enExample) 2010-09-30

Family

ID=39033325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009523960A Withdrawn JP2010507567A (ja) 2006-08-07 2007-08-07 併用療法

Country Status (12)

Country Link
US (1) US20100178271A1 (enExample)
EP (1) EP2056853A1 (enExample)
JP (1) JP2010507567A (enExample)
CN (1) CN101500595A (enExample)
AR (1) AR062271A1 (enExample)
AU (1) AU2007281677A1 (enExample)
BR (1) BRPI0715393A2 (enExample)
CA (1) CA2659337A1 (enExample)
IL (1) IL196559A0 (enExample)
MX (1) MX2009001445A (enExample)
RU (1) RU2009108289A (enExample)
WO (1) WO2008019371A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101631850B (zh) * 2007-01-09 2013-12-04 克里夫兰生物实验室公司 增加和转移造血干细胞的方法
EP2262494A2 (en) * 2008-02-29 2010-12-22 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of post-radiation tumor growth by an inhibitor of vasculogenesis
US10813917B2 (en) * 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
WO2011119738A2 (en) 2010-03-23 2011-09-29 The Johns Hopkins University Methods of treatment using stem cell mobilizers
US8546353B2 (en) 2010-05-06 2013-10-01 Glykos Finland Oy Compounds and combinations
EP2384759A1 (en) 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
ES2370986B1 (es) * 2010-06-08 2012-11-16 Institut Quimic De Sarria Cets Nuevos inhibidores de cxcr4 como agentes anti-vih
WO2012047339A2 (en) 2010-06-28 2012-04-12 The General Hospital Corporation Anti-cxcr4 as a sensitizer to cancer therapeutics
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SI3590949T1 (sl) 2010-10-01 2022-09-30 Modernatx, Inc. Ribonukleinske kisline, ki vsebujejo N1-metil-psevdouracil, in njihove uporabe
WO2012129073A2 (en) 2011-03-18 2012-09-27 University Of Virginia Patent Foundation Compositions and methods for tissue engineering and cell based therapies
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
PL2709991T3 (pl) 2011-05-16 2021-04-06 Genzyme Corporation Zastosowanie antagonistów CXCR4 w leczeniu zespołu WHIM, mielokateksji, neutropenii i limfocytopenii
WO2012174522A1 (en) * 2011-06-16 2012-12-20 Children's Medical Center Corporation Combined chemical modification of sphingosine-1-phosphate (s1p) and cxcr4 signalling pathways for hematopoietic stem cell (hsc) mobilization and engraftment
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
RU2649364C2 (ru) 2011-12-16 2018-04-02 Модерна Терапьютикс, Инк. Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP3520821A1 (en) 2012-04-02 2019-08-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
EP4169533A1 (en) 2013-02-28 2023-04-26 President and Fellows of Harvard College Methods and compositions for mobilizing stem cells
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2016191811A1 (en) * 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
EP3389720A1 (en) 2015-12-18 2018-10-24 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
EP4360567A3 (en) * 2016-10-24 2024-07-31 Yale University Aspiration device
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
SG11202003795YA (en) 2017-11-03 2020-05-28 Roemer & Heigl Gmbh Extraction of stem cells from bone marrow niches
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
AU2018378804B2 (en) * 2017-12-06 2025-10-02 Ensoma, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
WO2022101359A1 (en) 2020-11-12 2022-05-19 Roemer & Heigl Gmbh Reversible release of stem cells from bone marrow niches
WO2025224720A1 (en) 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
US6447766B1 (en) * 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
EP0713495B1 (en) * 1993-06-08 2003-11-05 Smithkline Beecham Corporation Methods of enhancing bioactivity of chemokines
DE4320478B4 (de) * 1993-06-21 2007-11-15 Robert Bosch Gmbh Fahrstabilitätsregler
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US6713052B1 (en) * 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
CN100335478C (zh) * 1999-12-17 2007-09-05 阿诺麦德股份有限公司 结合趋化因子受体的杂环化合物
DE60137944D1 (de) * 2000-09-15 2009-04-23 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
DK1317451T3 (da) * 2000-09-15 2006-12-18 Anormed Inc Kemokinreceptorbindende heterocykliske forbindelser
EP1322626B1 (en) * 2000-09-29 2008-11-05 Anormed Inc. Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
US6853731B1 (en) * 2000-09-30 2005-02-08 Keen Personal Technologies, Inc. Digital video recorder employing a unique ID to interlock with encrypted video programs stored on a storage device
WO2002081727A2 (en) * 2001-04-03 2002-10-17 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
EP2371361B1 (en) * 2001-07-31 2019-08-07 Genzyme Corporation Methods to mobilize progenitor/stem cells
WO2003048345A1 (en) * 2001-12-07 2003-06-12 Toolgen, Inc. Phenotypic screen of chimeric proteins
WO2004091518A2 (en) * 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
EP2374804A1 (en) * 2003-04-22 2011-10-12 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
EP1708703A4 (en) * 2003-12-11 2008-04-09 Anormed Inc CHEMOKIN RECEPTOR BINDING COMPOUNDS

Similar Documents

Publication Publication Date Title
JP2010507567A5 (enExample)
JP2009545620A5 (enExample)
RU2009108289A (ru) Комбинированная терапия
Pusic et al. Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells
RU2009107030A (ru) Комбинированная терапия
EP4353818A3 (en) Compositions, articles of manufacture and methods related to dosing in cell therapy
JP2007529532A5 (enExample)
KR102854375B1 (ko) 혈액 암을 위한 조합 치료법
JP2019503365A5 (enExample)
JP2010501159A5 (enExample)
JP2012067116A5 (enExample)
NZ707377A (en) Combination therapy methods for treating proliferative diseases
TWI759316B (zh) Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
MX358491B (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
JP2009545600A5 (enExample)
JP2021046446A (ja) グルココルチコイド及びｅｄｏ−ｓ１０１を含む組合せ
CO6771406A2 (es) Una composición combinada
JP2012517449A5 (enExample)
JP2013541583A5 (enExample)
MA56827B2 (fr) Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
JP2023012503A5 (enExample)
JP2009506054A5 (enExample)
JP2013540734A5 (enExample)
JP2017527551A5 (enExample)
CN101991579A (zh) 熊果酸作为抗结肠肿瘤药物的应用